Loading patent…
AssigneeEmerald Therapeutics, Inc.
InventorsBrian M. Frezza, Bradley M. Bond, Collin A. Melton, Catherine L. Hofler, Daniel J. Kleinbaum
Estimating the term…
An approach to designing a polynucleotide probe to hybridize selectively to a target polynucleotide sequence involves calculating the final concentration of the intended binding product between a candidate probe and the target sequence. The calculation takes into consideration the binding reaction between the candidate probe and the target fragment on the target sequence, as well as various other binding reactions, involving either the probe or the target fragment, that interfere with the intended binding reaction. In contrast to the conventional technology, which attempts to determine the entire structure of the target polynucleotide, this approach only needs to determine the binding dynamics that impact on the intended probe-target fragment binding. The approach does not require determination of the structure of the involved sequences.
A method for obtaining information on how effectively a nucleotide probe selectively binds a target fragment in a target nucleotide sequence in a sample, comprising:
A computer system for obtaining information on how effectively a nucleotide probe selectively binds a target fragment in a target nucleotide sequence in a sample, said system comprising a processor, a memory and program code which, when executed by the processor, configures the system to:
A non-transitory computer-readable medium for obtaining information on how effectively a nucleotide probe selectively binds a target fragment in a target nucleotide sequence in a sample, comprising program code which, when executed, configures a computer to:
Dependencies are inferred from the claim text.